169 related articles for article (PubMed ID: 7683664)
21. Characterization of the interaction between plasminogen and staphylokinase.
Lijnen HR; De Cock F; Van Hoef B; Schlott B; Collen D
Eur J Biochem; 1994 Aug; 224(1):143-9. PubMed ID: 8076635
[TBL] [Abstract][Full Text] [Related]
22. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen HR
Biochim Biophys Acta; 1994 Feb; 1204(2):235-42. PubMed ID: 8142464
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
24. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
25. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
Rijken DC; Groeneveld E; Kluft C; Nieuwenhuis HK
Biochem J; 1988 Oct; 255(2):609-15. PubMed ID: 2974279
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
27. Effect of staphylokinase concentration of plasminogen activation.
Arai K; Mimuro J; Madoiwa S; Matsuda M; Sako T; Sakata Y
Biochim Biophys Acta; 1995 Aug; 1245(1):69-75. PubMed ID: 7654768
[TBL] [Abstract][Full Text] [Related]
28. The mechanism of a bacterial plasminogen activator intermediate between streptokinase and staphylokinase.
Sazonova IY; Houng AK; Chowdhry SA; Robinson BR; Hedstrom L; Reed GL
J Biol Chem; 2001 Apr; 276(16):12609-13. PubMed ID: 11278483
[TBL] [Abstract][Full Text] [Related]
29. Kinetic properties of the activator complexes plasmin--staphylokinase and plasmin(ogen)--streptokinase in vitro.
Sazonova IY; Aisina RB; Muhametova LI; Varfolomeyev SD
Biochemistry (Mosc); 1999 Jan; 64(1):66-74. PubMed ID: 9986915
[TBL] [Abstract][Full Text] [Related]
30. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
Suenson E; Thorsen S
Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
[TBL] [Abstract][Full Text] [Related]
31. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
32. [Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin].
Hrynenko TV; Iusova OI; Zadorozhna MB; Makohonenko IeM
Ukr Biokhim Zh (1999); 2002; 74(6):83-90. PubMed ID: 12924019
[TBL] [Abstract][Full Text] [Related]
33. Regulation of macrophage receptor-bound plasmin by autoproteolysis.
Falcone DJ; Borth W; McCaffrey TA; Mathew J; McAdam K
J Biol Chem; 1994 Dec; 269(51):32660-6. PubMed ID: 7528219
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin.
Cederholm-Williams SA; De Cock F; Lijnen HR; Collen D
Eur J Biochem; 1979 Oct; 100(1):125-32. PubMed ID: 158524
[TBL] [Abstract][Full Text] [Related]
35. Enhanced activation of bound plasminogen on Staphylococcus aureus by staphylokinase.
Mölkänen T; Tyynelä J; Helin J; Kalkkinen N; Kuusela P
FEBS Lett; 2002 Apr; 517(1-3):72-8. PubMed ID: 12062412
[TBL] [Abstract][Full Text] [Related]
36. Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma.
Ueshima S; Silence K; Collen D; Lijnen HR
Thromb Haemost; 1993 Sep; 70(3):495-9. PubMed ID: 8259556
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the murine plasma fibrinolytic system.
Lijnen HR; van Hoef B; Beelen V; Collen D
Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents.
Miles LA; Burnier JP; Verlander MS; Goodman M; Kleiss AJ; Griffin JH
Blood; 1981 Jun; 57(6):1015-24. PubMed ID: 6452920
[TBL] [Abstract][Full Text] [Related]
39. Chimerism reveals a role for the streptokinase Beta -domain in nonproteolytic active site formation, substrate, and inhibitor interactions.
Gladysheva IP; Sazonova IY; Chowdhry SA; Liu L; Turner RB; Reed GL
J Biol Chem; 2002 Jul; 277(30):26846-51. PubMed ID: 12016220
[TBL] [Abstract][Full Text] [Related]
40. Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
Edelberg JM; Pizzo SV
Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):79-84. PubMed ID: 1381585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
